Given that resected tumors have a relatively large population of pro-tumoral macrophages in GBM at the baseline, which are increased in response to radiotherapy, Almahariq et al. tested the CSF-1R inhibitor BLZ-945, which reduces pro-tumoral macrophage polarization and improves the response to radiotherapy [103]. Here, CSF1R is linked to glioblastoma.